Allianz Asset Management Gmb H Adverum Biotechnologies, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$2.08 - $3.6 $125,773 - $217,684	-60,468 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $574,449 - $1.81 Million	-170,967 Reduced 73.87%	60,468 $212,000
Q1 2021 May 13, 2021	SELL	$9.26 - $14.36 $46,337 - $71,857	-5,004 Reduced 2.12%	231,435 $2.28 Million
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $331,135 - $479,877	-33,652 Reduced 12.46%	236,439 $2.56 Million
Q3 2020 Nov 13, 2020	BUY	$10.3 - $21.64 $313,974 - $659,652	30,483 Added 12.72%	270,091 $2.78 Million
Q2 2020 Aug 14, 2020	SELL	$8.53 - $25.64 $533,960 - $1.61 Million	-62,598 Reduced 20.71%	239,608 $5 Million
Q1 2020 May 14, 2020	BUY	$7.98 - $16.32 $282,412 - $577,564	35,390 Added 13.26%	302,206 $2.95 Million
Q4 2019 Feb 13, 2020	BUY	$5.12 - $12.22 $1.01 Million - $2.4 Million	196,484 Added 279.37%	266,816 $3.07 Million
Q3 2019 Nov 13, 2019	BUY	$5.24 - $15.89 $368,539 - $1.12 Million	70,332 New	70,332 $383,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $607M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.